Results 1 to 10 of about 7,945 (149)

Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial. [PDF]

Addiction
Abstract Background and aims By assessing neuroaffective response to motivationally relevant cues before a quit attempt, we have shown that smokers who attribute greater incentive salience to cigarette‐related cues than non‐cigarette‐related rewards (Sign‐trackers, ST) benefit more from varenicline compared with smokers with the opposite neuroaffective
Versace F, Green CE, Cui Y, Robinson JD, Deweese MM, Minnix JA, Kypriotakis G, Kim S, Karam-Hage M, Cinciripini PM.   +9 more
europepmc   +2 more sources

Investigation of varenicline and tropisetron in latent inhibition and novel object recognition in mice. [PDF]

Sci Rep
There is currently no treatment for cognitive-impairment associated with schizophrenia (CIAS). Animal and human studies suggest that nicotinic cholinergic agonists and 5-HT3 antagonists have potential therapeutic benefits.
Lizarraga-Valderrama LR, Williams S, Watson DJG, Granger KT, Gibson CL, Moran PM.   +5 more
europepmc   +2 more sources

Electronic Cigarettes Versus Varenicline for Smoking Cessation: A Systematic Review and Meta-analysis of in-person Support Augmentation Strategies. [PDF]

Indian J Community Med
Tobacco smoking is a global health crisis, causing over 8 million deaths annually, including 1.3 million in India. The rise of electronic cigarettes (e-cigarettes) has raised questions about their effectiveness compared to traditional aids like ...
Sinha A, Wasnik M, Chevvuri R.
europepmc   +2 more sources

Comparative Effectiveness of Cytisinicline and Varenicline for Smoking Cessation: A Matching-Adjusted Indirect Comparison (MAIC). [PDF]

J Health Econ Outcomes Res
# Background Pharmacologic options for supporting smoking cessation remain limited. Cytisinicline is a plant-based alkaloid that selectively binds to α4β2 nicotinic acetylcholine receptors, reducing nicotine craving and withdrawal symptoms, and has ...
Rubinstein M, Rowe D, Perdok R, Jacobs C.   +3 more
europepmc   +2 more sources

Utilization of varenicline among Kansas Medicaid enrollees. [PDF]

PLoS One
BackgroundSmoking prevalence among Medicaid beneficiaries is twice that of privately insured adults, yet effective smoking cessation treatments remain underutilized.
Machado NM, Katz AJ, Richter KP, Ellerbeck EF.   +3 more
europepmc   +2 more sources

Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease

Brazilian Journal of Medical and Biological Research, 2021
The beneficial effects of drugs that act via nicotinic acetylcholine receptors (nAChRs) on Parkinson's disease (PD) symptomatology may explain the negative correlation between cigarette smoking and risk of this neurological condition.
A. Ribeiro-Carvalho, P.H. Leal-Rocha, J. Isnardo-Fernandes, U.C. Araújo, Y. Abreu-Villaça, C.C. Filgueiras, A.C. Manhães   +6 more
doaj   +1 more source

The Antiviral Activity of Varenicline against Dengue Virus Replication during the Post-Entry Stage

Biomedicines, 2023
Dengue virus (DENV) poses a significant global health challenge, with millions of cases each year. Developing effective antiviral drugs against DENV remains a major hurdle. Varenicline is a medication used to aid smoking cessation, with anti-inflammatory
Ching-Lin Lin, Yan-Tung Kiu, Ju-Ying Kan, Yu-Jen Chang, Ping-Yi Hung, Chih-Hao Lu, Wen-Ling Lin, Yow-Wen Hsieh, Jung-Yie Kao, Nien-Jen Hu, Cheng-Wen Lin   +10 more
doaj   +1 more source

Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression

Journal of Pharmacological Sciences, 2020
Varenicline is a widely used and effective drug for smoking cessation. We previously reported that varenicline aggravates atherosclerosis in apolipoprotein E knockout (ApoE KO) mice.
Mitsuhisa Koga, Yuki Kanaoka, Mana Okamoto, Yuki Nakao, Koshun Inada, Saki Takayama, Yasufumi Kataoka, Atsushi Yamauchi   +7 more
doaj   +1 more source

Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials

Indian Journal of Psychiatry, 2023
According to the Global Burden of Disease (GBD) Study conducted in 2019, smoking tobacco leads to over 8 million deaths each year. Hence, it is crucial to identify optimal smoking cessation therapy. To compare the efficacy of varenicline versus bupropion
Ashish R. Patel, Jigar R. Panchal, Chetna K. Desai   +2 more
doaj   +1 more source

Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages

Journal of Pharmacological Sciences, 2020
Varenicline is a widely used and effective drug for smoking cessation. We have previously reported experimental evidence suggesting that varenicline increases the risk of cardiovascular events.
Mitsuhisa Koga, Yuki Kanaoka, Koshun Inada, Sai Omine, Yasufumi Kataoka, Atsushi Yamauchi   +5 more
doaj   +1 more source